Overview

ABT-378/Ritonavir in Combination With Reverse Transcriptase Inhibitors in Antiretroviral Naïve HIV-Infected Subjects

Status:
Completed
Trial end date:
2005-04-01
Target enrollment:
Participant gender:
Summary
To assess the safety, tolerability and antiviral activity of lopinavir/ritonavir when administered orally in antiretroviral-HIV-1 infected subjects.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Abbott
Treatments:
Lamivudine
Lopinavir
Reverse Transcriptase Inhibitors
Ritonavir
Stavudine